EUCTR2017-002093-40-NL进行中（未招募）1 期
68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinoma - PSMA-PET imaging for advanced ACC/SDC
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Radboudumc
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •locally advanced, recurrent or metastatic ACC/SDC
- •Age = 18 years old
- •Ability to provide written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •Contra-indication for PET imaging (pregnancy, breast feeding, severe claustrophobia)
- •Impaired renal function: MDRD <30 ml/min/1,73 m2
- •Impaired liver function: AST and ALT = 2.5 x ULN (=5 x ULN for patients with liver metastases)
研究者
相似试验
已完成
不适用
68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma or salivary duct carcinomaAdenoid cystic carcinomaNL-OMON44299Radboud Universitair Medisch Centrum25
进行中（未招募）
1 期
Investigation of 68GaPSMA PET/CT as an imaging biomarker in solid tumorsadvanced/metastatic solid tumorsMedDRA version: 20.0Level: LLTClassification code 10027477Term: Metastatic carcinomaSystem Organ Class: 100000004864EUCTR2016-004376-21-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS400
招募中
2 期
PETCT and MRI guided boost for prostate cancer radiotherapyCTRI/2022/09/045258Varian Medical System
进行中（未招募）
1 期
Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management. The ProsPERo TrialMales 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on palliative systemic treatment and considered for further salvage therapyMedDRA version: 19.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10068979Term: Imaging procedureSystem Organ Class: 10022891 - InvestigationsEUCTR2016-000842-79-BEInstitut Jules Bordet75
进行中（未招募）
1 期
Octreotide PET/CT scan for the imaging of disease activity in neurologic and cardiac sarcoidosis.Sarcoidosis.EUCTR2016-002160-14-NLSt. Antonius Hospital